Search details
1.
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.
Future Oncol
; 20(15): 969-980, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38095056
2.
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Future Oncol
; 19(19): 1319-1329, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-37212796
3.
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.
Proc Natl Acad Sci U S A
; 115(26): E6030-E6038, 2018 06 26.
Article
in English
| MEDLINE | ID: mdl-29875142
4.
Generation of conditional oncogenic chromosomal translocations using CRISPR-Cas9 genomic editing and homology-directed repair.
J Pathol
; 242(1): 102-112, 2017 05.
Article
in English
| MEDLINE | ID: mdl-28188619
5.
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
J Thorac Oncol
; 18(4): 516-526, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36240971
6.
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
J Clin Oncol
; 41(35): 5363-5375, 2023 Dec 10.
Article
in English
| MEDLINE | ID: mdl-37689979
7.
SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
JCO Precis Oncol
; 6: e2200088, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35952318
8.
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.
Front Oncol
; 11: 638482, 2021.
Article
in English
| MEDLINE | ID: mdl-33968735
9.
ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers.
Clin Cancer Res
; 24(22): 5499-5501, 2018 11 15.
Article
in English
| MEDLINE | ID: mdl-30135146
10.
Homo- and hetero-oligomerization of the c-Abl kinase and Abelson-interactor-1.
Cancer Res
; 63(4): 873-7, 2003 Feb 15.
Article
in English
| MEDLINE | ID: mdl-12591740
11.
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Cancer Res
; 75(6): 1035-45, 2015 Mar 15.
Article
in English
| MEDLINE | ID: mdl-25596284
12.
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Cancer Discov
; 5(8): 842-9, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-25971939
13.
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.
Dis Model Mech
; 3(1-2): 111-9, 2010.
Article
in English
| MEDLINE | ID: mdl-20007486
14.
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
Genes Dev
; 20(11): 1496-510, 2006 Jun 01.
Article
in English
| MEDLINE | ID: mdl-16705038
Results
1 -
14
de 14
1
Next >
>>